feedback

Course Director

Richard Kim, MD
Richard Kim, MD

Moffitt Cancer Center
Tampa, Florida

Faculty

Karon Martyn
Karon Martyn, MSN, ANP-BC, AOCNP

Abington-Jefferson Health
Abington, Pennsylvania

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CE
Credit Amount:0.75 Credits
Release Date:2018-May-30
Expiration Date:2019-May-29
Estimated Time for Completion:45 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts in metastatic colorectal cancer (mCRC) discuss evidence for the efficacy of approved therapies in the management of mCRC with a focus on later-line treatment strategies. They examine and compare the safety profiles of available oral oncolytic agents and describe strategies to manage adverse events associated with these therapies.

Upon completion of this activity, participants will be able to:

  • Cite current treatment guidelines for metastatic colorectal cancer (mCRC)
  • Discuss evidence for the efficacy of approved therapies in the management of metastatic colorectal cancer throughout the disease continuum
  • Compare safety profiles of available agents and describe strategies to manage adverse events associated with available therapies including dose modifications
  • Assess administration of oral agents and monitor for treatment adherence

Target Audience

This activity has been designed to meet the educational needs of oncologists, oncology nurses, and other clinicians involved in the management of patients with mCRC.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of metastatic colorectal cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 30, 2018 - May 29, 2019
Time to Complete: 45 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CE activity during the past 12 months.

Course Director and Moderator

Richard Kim, MD
Associate Professor
Service Chief
GI Medical Oncology
Moffitt Cancer Center
Tampa, Florida

Richard Kim, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company.
Grant/Research Support from Bayer Corporation; Bristol-Myers Squibb Company; and Eisai Inc.
Speakers Bureau participant with Eli Lilly and Company and Taiho Ventures, LLC.
Advisory Board for Bayer Corporation.
Richard Kim, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: regorafenib, trifluridine/tipiracil (TAS-102), bevacizumab, atezolizumab, and cobimetinib for the management of colorectal cancer.

Faculty

Karon Martyn, MSN, ANP-BC, AOCNP
Nurse Practitioner
GI Medical Oncology
Abington-Jefferson Health
Abington, Pennsylvania

Karon Martyn, MSN, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support from Medscape in the form of participation in a round table discussion and Horizon as a part of a planning committee for an oncology summit.
Karon Martyn, MSN, ANP-BC, AOCNP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: regorafenib, trifluridine/tipiracil (TAS-102), bevacizumab, atezolizumab, and cobimetinib for the management of colorectal cancer.

CME Reviewers

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Kaushal Patel, MD
Internal Medicine
Camp Hill, Pennsylvania

Kaushal Patel, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Amita B. Patel, MSN, RN, AOCNP, NP-C
Regional Cancer Care Associates LLC
East Brunswick, New Jersey

Amita B. Patel, MSN, RN, AOCNP, NP-C, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared with ABIM through the ACCME’s Program Reporting and Activity System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour(s).

Providership

This CME/MOC/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Taiho Oncology, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.